AC Immune SA ROCE
Cos'è ROCE di AC Immune SA?
ROCE di AC Immune SA è -39.43%
Qual è la definizione di ROCE?
Il ritorno sul capitale investito (ROCE) è un rapporto finanziario che misura la redditività di un'azienda e l'efficienza con cui viene utilizzato il suo capitale.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE di aziende nel Health Care settore su NASDAQ rispetto a AC Immune SA
Cosa fa AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Aziende con roce simili a AC Immune SA
- Entree Resources ha ROCE di -39.74%
- E-COM (Aus) Pty Ltd ha ROCE di -39.73%
- Good2 Go4 Corp ha ROCE di -39.66%
- Ascendis Pharma A/S ha ROCE di -39.57%
- Therealreal Inc ha ROCE di -39.56%
- Ascentage Pharma Grp Intl ha ROCE di -39.45%
- AC Immune SA ha ROCE di -39.43%
- Sangamo Therapeutics ha ROCE di -39.40%
- Churchill Capital Corp IV ha ROCE di -39.36%
- InflaRx N.V ha ROCE di -39.33%
- Fosterville South Exploration ha ROCE di -39.22%
- Inogen Inc ha ROCE di -39.17%
- China Zenix Auto International ha ROCE di -39.05%